FHTX
Foghorn Therapeutics Inc.
FHTX's fundamentals are strong: revenue more than tripled and its operating margin went from −353% to 2.1%, though free cash flow was negative. Its PE isn't a useful guide right now because of how its recent earnings were reported.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
FHTX Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Weak | |
| Strong |
FHTX's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
FHTX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 34x | $2.05 | — |
| Cheap | N/A | N/A | N/A |
| Fair | N/A | N/A | N/A |
| Expensive | N/A | N/A | N/A |
Historical ranges are pointers, not guarantees.
FHTX has the edge over NVO in the historical PE scenario, which offers more potential upside but is not a forecast.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
FHTX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect FHTX's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
FHTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.06 | +$1.12 |
| Q2 2026 | -$0.99 | +$0.13 |
| Q1 2026 | -$1.17 | +$0.12 |
| Q4 2025 | -$1.18 | +$0.40 |
| Q3 2025 | -$1.06 | +$0.86 |
| Q2 2025 | -$1.12 | +$0.83 |
| Q1 2025 | -$1.29 | +$0.91 |
| Q4 2024 | -$1.58 | +$0.76 |
FHTX has returned to profit: it earned $0.06 per share over the past year, after losing money the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
FHTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $83.5M | +925% |
| Q2 2026 | $16.1M | +113% |
| Q1 2026 | $3.3M | -45% |
| Q4 2025 | $9.2M | +224% |
| Q3 2025 | $8.2M | +4.4% |
| Q2 2025 | $7.6M | +9.7% |
| Q1 2025 | $6M | +18% |
| Q4 2024 | $2.9M | -50% |
FHTX's revenue is growing: $84M last quarter, up 925% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 68% | +295 points |
| Q2 2026 | -55% | +224 points |
| Q1 2026 | -660% | -275 points |
| Q4 2025 | -258% | +582 points |
| Q3 2025 | -227% | +79 points |
| Q2 2025 | -279% | +108 points |
| Q1 2025 | -385% | +173 points |
| Q4 2024 | -841% | -399 points |
FHTX has the edge over NVO on profitability, with a higher operating margin.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over FHTX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
FHTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$18.3M | +$610K |
| Q2 2026 | -$17.9M | +$3.1M |
| Q1 2026 | -$25.3M | -$1.3M |
| Q4 2025 | -$22.3M | +$2.7M |
| Q3 2025 | -$18.9M | +$2.5M |
| Q2 2025 | -$21M | +$4.5M |
| Q1 2025 | -$24M | +$5.5M |
| Q4 2024 | -$25M | +$2.6M |
FHTX has burned cash in almost every quarter: −$84M over the past year, against −$89M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over FHTX on cash generation, producing positive trailing cash flow while its opponent burns cash.
FHTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.8% | +2M shares |
| 1 year | +15% | +9.6M shares |
| 3 years | +73% | +30.6M shares |
| 5 years | +96% | +35.6M shares |
| Available history | +228% | +50.5M shares |
FHTX has 73M diluted shares, up 15% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over FHTX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
FHTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -21.0x | Net Cash |
FHTX has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
FHTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.3 | Neutral |
| Stochastic | 3.6 | Oversold |
FHTX's weekly RSI is 35 (neutral) and its Stochastic is 4 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
FHTX PE vs Healthcare Sector
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
FHTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.17 | 5.5% below |
| 20 week MA | $4.10 | 50% below |
| 50 week MA | $4.60 | 55% below |
| 100 week MA | $4.62 | 56% below |
| 200 week MA | $5.55 | 63% below |
FHTX is in a downtrend: it's below all five of its weekly moving averages, and 63% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over FHTX on trend strength, trading above more of its moving averages.
FHTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18.1 | $24.6 | +36% |
| 2021 | $24.6 | $21.2 | -14% |
| 2022 | $21.2 | $5.70 | -73% |
| 2023 | $5.70 | $6.45 | +13% |
| 2024 | $6.45 | $4.82 | -25% |
| 2025 | $4.82 | $5.40 | +12% |
| 2026 YTD | $5.40 | $2.05 | -62% |
FHTX has finished lower in three of the last six years. It's down 62% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over FHTX on returns for 2026, with the stronger performance.